Humanigen Forum: Community User: Rothschild123

Und schon geht es aufwärts! 😄

BURLINGAME, Calif. & DUBLIN & LONDON--(BUSINESS WIRE)-- Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced today that lenzilumab is now available for certain hospitalized COVID-19 patients through its newly-launched Managed Access Program (“LenzMAP™”). Clinigen Group plc (“Clinigen”), a global pharmaceutical Services and Products company, is implementing the program. Lenzilumab is an investigational product and is not currently authorized or approved in any country. Clinigen is an expert in delivering specialty therapies on a named-patient basis in the UK and Europe.

Unter 2… 😭 und man sieht keinen Boden… freier Fall

he said, this should not be seen as the "finish line" because the virus and future variants cannot be eradicated - instead "we must learn to live with Covid in the same way we live with flu".

England's Plan B measures are to end from next Thursday, with mandatory face coverings in public places and Covid passports both dropped, Boris Johnson has announced.

In England sind alle Covid Einschränkungen weg…. Ob die jetzt alles auf Medikamente gesetzt haben und auch für schwere Fälle vorbereitet sind?

Die müssen sich noch vor angepassten-Omicron-Impfung melden. Aus Israel-Studie zu entnehmen, dass 4e Dosis kein Nutzen bringt

Noch 😀

Es lebt

Lenzilumab plus standard of care (SOC), resulted in an estimated cost savings of $13,190 per patient (net savings of $3,190, after an assumed price of $10,000 for lenzilumab) in those receiving remdesivir with baseline C-Reactive Protein (CRP) levels <150 mg/L, and aged <85 years For COVID-19 patients requiring ICU admission and invasive mechanical ventilation, the average healthcare cost is $78,245 per patient Despite increasing vaccinations, the number of COVID-19 cases, hospitalizations and deaths continues to increase, demonstrating the urgent need for both clinically effective and cost-effective variant-agnostic treatments for hospitalized patients

Humanigen Announces Peer-Reviewed Publication in The Journal of Medical Economics Demonstrating the Clinical and Economic Benefits of Lenzilumab Jan 18, 2022

Vielen Dank für die News

Danke 🤗

Mal schauen, wie es sich jetzt weiter entwickelt 🤞🤞🤞

https://ir.humanigen.com/English/news/news-details/2022/Humanigen-Aligns-with-FDA-on-Potential-Registration-Phase-3-Study-for-Lenzilumab-with-CAR-T/default.aspx